Professor Bruno Silva-Santos is a Group Leader and Vice-Director of Instituto de Medicina Molecular, and Professor at the Faculty of Medicine of the University of Lisbon. Professor Silva-Santos completed his PhD in Immunology with Michael J. Owen at Cancer Research UK, and trained as a post-doc with Professor Adrian Hayday at King’s College London. Since establishing his independent group in 2006 at Instituto de Medicina Molecular in Lisbon, he has received Starting and Consolidator Grants from the European Research Council (ERC) and Installation and Young Investigator Grants from the European Molecular Biology Organisation (EMBO).

Professor Silva-Santos research is mostly dedicated to γδ T cells, having dissected novel molecular mechanisms of their differentiation and tumour cell recognition, published circa 90 papers in top international peer-reviewed journals. His translational work has been recognised with a variety of awards and the nomination to the European Academy of Tumour Immunology. This led in 2013 to a start-up company focused on cancer immunotherapy, Lymphact, which was acquired in 2018 by GammaDelta Therapeutics.